Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > crosstalk between senescent cells and CD8 T cell-dependent a

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 06, 2023 11:33am

105 Views

Post# 35383121

RE:RE:crosstalk between senescent cells and CD8 T cell-dependent a

Once again -- should read: "...results in the ability of turning "cold" tumors into "hot" tumors .. through innate and adaptive immune responses to treat a variety of cancers, and overcoming the issue of T-Cell exhaustion ... "

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities